Where's the value in Pfizer's $17bn Hospira buy?
This article was originally published in Scrip
Executive Summary
With Pfizer's pending $17bn acquisition of Hospira there's a lot of interest in the target company's biosimilar portfolio, given the potential for cheaper copies of biological medicines to steal substantial market share from major drug makers, but the most valuable part of the deal for Pfizer could be the addition of Hospira's generic injectable products and manufacturing capabilities.
You may also be interested in...
Keeping Track: Approvals, A Burst Of Submissions, And Some Priority Reviews
The latest drug development news and highlights from our US FDA Performance Tracker.
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.